| Product Code: ETC10756620 | Publication Date: Apr 2025 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 65 | No. of Figures: 34 | No. of Tables: 19 | |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Netherlands PD-1 Non-Small Cell Lung Cancer Market Overview |
3.1 Netherlands Country Macro Economic Indicators |
3.2 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, 2021 & 2031F |
3.3 Netherlands PD-1 Non-Small Cell Lung Cancer Market - Industry Life Cycle |
3.4 Netherlands PD-1 Non-Small Cell Lung Cancer Market - Porter's Five Forces |
3.5 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.6 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume Share, By Therapy Type, 2021 & 2031F |
3.7 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume Share, By Treatment Stage, 2021 & 2031F |
3.8 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume Share, By Mode of Action, 2021 & 2031F |
3.9 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Netherlands PD-1 Non-Small Cell Lung Cancer Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of non-small cell lung cancer in the Netherlands |
4.2.2 Growing adoption of PD-1 inhibitors as a preferred treatment option |
4.2.3 Advancements in medical research leading to the development of innovative PD-1 inhibitors |
4.3 Market Restraints |
4.3.1 High cost associated with PD-1 inhibitors |
4.3.2 Stringent regulatory requirements for approval and reimbursement of PD-1 inhibitors in the Netherlands |
5 Netherlands PD-1 Non-Small Cell Lung Cancer Market Trends |
6 Netherlands PD-1 Non-Small Cell Lung Cancer Market, By Types |
6.1 Netherlands PD-1 Non-Small Cell Lung Cancer Market, By Drug Type |
6.1.1 Overview and Analysis |
6.1.2 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Drug Type, 2021 - 2031F |
6.1.3 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By PD-1 Inhibitors, 2021 - 2031F |
6.1.4 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By PD-L1 Inhibitors, 2021 - 2031F |
6.1.5 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Combination Therapy, 2021 - 2031F |
6.1.6 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Monotherapy, 2021 - 2031F |
6.1.7 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Adjuvant Therapy, 2021 - 2031F |
6.2 Netherlands PD-1 Non-Small Cell Lung Cancer Market, By Therapy Type |
6.2.1 Overview and Analysis |
6.2.2 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Immunotherapy, 2021 - 2031F |
6.2.3 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Chemotherapy, 2021 - 2031F |
6.2.4 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Radiation Therapy, 2021 - 2031F |
6.2.5 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Surgery, 2021 - 2031F |
6.2.6 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Palliative Care, 2021 - 2031F |
6.3 Netherlands PD-1 Non-Small Cell Lung Cancer Market, By Treatment Stage |
6.3.1 Overview and Analysis |
6.3.2 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By First-Line Treatment, 2021 - 2031F |
6.3.3 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Second-Line Treatment, 2021 - 2031F |
6.3.4 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Advanced-Stage Treatment, 2021 - 2031F |
6.3.5 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Recurrent Cancer Treatment, 2021 - 2031F |
6.3.6 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Metastatic Cancer Treatment, 2021 - 2031F |
6.4 Netherlands PD-1 Non-Small Cell Lung Cancer Market, By Mode of Action |
6.4.1 Overview and Analysis |
6.4.2 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Targeted Therapy, 2021 - 2031F |
6.4.3 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Checkpoint Inhibitors, 2021 - 2031F |
6.4.4 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Biomarker-Based Therapy, 2021 - 2031F |
6.4.5 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Immune Checkpoint Modulation, 2021 - 2031F |
6.4.6 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By T-Cell Activation, 2021 - 2031F |
6.5 Netherlands PD-1 Non-Small Cell Lung Cancer Market, By End User |
6.5.1 Overview and Analysis |
6.5.2 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Hospitals, 2021 - 2031F |
6.5.3 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Research Labs, 2021 - 2031F |
6.5.4 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Oncology Centers, 2021 - 2031F |
6.5.5 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Clinics, 2021 - 2031F |
6.5.6 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Diagnostic Centers, 2021 - 2031F |
7 Netherlands PD-1 Non-Small Cell Lung Cancer Market Import-Export Trade Statistics |
7.1 Netherlands PD-1 Non-Small Cell Lung Cancer Market Export to Major Countries |
7.2 Netherlands PD-1 Non-Small Cell Lung Cancer Market Imports from Major Countries |
8 Netherlands PD-1 Non-Small Cell Lung Cancer Market Key Performance Indicators |
8.1 Patient survival rate post PD-1 inhibitor treatment |
8.2 Rate of adoption of PD-1 inhibitors as a first-line treatment option |
8.3 Number of ongoing clinical trials evaluating new PD-1 inhibitors |
8.4 Average time to market approval for PD-1 inhibitors in the Netherlands |
9 Netherlands PD-1 Non-Small Cell Lung Cancer Market - Opportunity Assessment |
9.1 Netherlands PD-1 Non-Small Cell Lung Cancer Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.2 Netherlands PD-1 Non-Small Cell Lung Cancer Market Opportunity Assessment, By Therapy Type, 2021 & 2031F |
9.3 Netherlands PD-1 Non-Small Cell Lung Cancer Market Opportunity Assessment, By Treatment Stage, 2021 & 2031F |
9.4 Netherlands PD-1 Non-Small Cell Lung Cancer Market Opportunity Assessment, By Mode of Action, 2021 & 2031F |
9.5 Netherlands PD-1 Non-Small Cell Lung Cancer Market Opportunity Assessment, By End User, 2021 & 2031F |
10 Netherlands PD-1 Non-Small Cell Lung Cancer Market - Competitive Landscape |
10.1 Netherlands PD-1 Non-Small Cell Lung Cancer Market Revenue Share, By Companies, 2024 |
10.2 Netherlands PD-1 Non-Small Cell Lung Cancer Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here